Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.47 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.47 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 2/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 3/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18954274 | 0.89 | KDM4E (0.49) | KDM4EPOLBGAALTA4HALDH1A1 | |
| SCHEMBL17422280 | 0.89 | KDM4E (0.48) | KDM4ELTA4HALDH1A1 | |
| SCHEMBL17422292 | 0.83 | FFAR4 (0.38) | KDM4EPOLBGAAALDH1A1HTT | |
| SCHEMBL18879739 | 0.83 | CCR4 (0.52) | KDM4EPSMB1PSMB5PSMB2ESR1 | |
| SCHEMBL18879730 | 0.82 | CCR4 (0.51) | KDM4EPSMB1PSMB5PSMB2ESR1 | |
| SCHEMBL17422296 | 0.81 | HPGD (0.54) | KDM4EPOLBALDH1A1TDP1 | |
| SCHEMBL17422241 | 0.80 | HPGD (0.52) | KDM4EPOLBALDH1A1TDP1 | |
| SCHEMBL17431866 | 0.80 | HRH3 (0.52) | PSMB1PSMB5PSMB2ESR1ESR2 | |
| SCHEMBL17422310 | 0.79 | LMNA (0.37) | KDM4EPOLBALDH1A1TDP1HTT | |
| SCHEMBL21122443 | 0.79 | PSMB1 (0.48) | KDM4EPSMB1PSMB5PSMB2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3166945-B1 | NOVEL TRIAZOLOPYRIMIDINONE OR TRIAZOLOPYRIDINONE DERIVATIVES, AND USE THEREOF | ST PHARM CO LTD (KR) | 2019-10-09 | — | — | EP | disclosed |
| US-10179785-B2 | Imidazotriazinone or imidazopyrazinone derivatives, and use thereof | ST PHARM CO., LTD. (KR) | 2019-01-15 | — | — | US | disclosed |
| US-9914737-B2 | Triazolopyrimidinone or triazolopyridinone derivatives, and use thereof | ST PHARM CO., LTD. (KR) | 2018-03-13 | — | — | US | disclosed |
| US-20170166572-A1 | NOVEL IMIDAZOTRIAZINONE OR IMIDAZOPYRAZINONE DERIVATIVES, AND USE THEREOF | ST PHARM CO., LTD. (KR) | 2017-06-15 | — | — | US | disclosed |
| US-20170145016-A1 | NOVEL TRIAZOLOPYRIMIDINONE OR TRIAZOLOPYRIDINONE DERIVATIVES, AND USE THEREOF | ST PHARM CO., LTD. (KR) | 2017-05-25 | — | — | US | disclosed |
| EP-3166945-A2 | NOVEL TRIAZOLOPYRIMIDINONE OR TRIAZOLOPYRIDINONE DERIVATIVES, AND USE THEREOF | ST Pharm Co. Ltd. (KR) | 2017-05-17 | — | — | EP | disclosed |
| EP-3166946-A2 | NOVEL IMIDAZOTRIAZINONE OR IMIDAZOPYRAZINONE DERIVATIVES, AND USE THEREOF | ST Pharm Co. Ltd. (KR) | 2017-05-17 | — | — | EP | disclosed |
| WO-2016006974-A2 | NOVEL TRIAZOLOPYRIMIDINONE OR TRIAZOLOPYRIDINONE DERIVATIVES, AND USE THEREOF | ST PHARM CO., LTD. (KR) | 2016-01-14 | — | — | WO | disclosed |
| WO-2016006975-A2 | NOVEL IMIDAZOTRIAZINONE OR IMIDAZOPYRAZINONE DERIVATIVES, AND USE THEREOF | ST PHARM CO., LTD. (KR) | 2016-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145016-A1 | NOVEL TRIAZOLOPYRIMIDINONE OR TRIAZOLOPYRIDINONE DERIVATIVES, AND USE THEREOF | TNKS1BP1, TNKS, TPI1 | KDM4E 1255/4885POLB 1508/4885PSMB1 2338/4885 |
| US-10179785-B2 | Imidazotriazinone or imidazopyrazinone derivatives, and use thereof | TNKS1BP1, TPI1, TPMT | KDM4E 1073/4885POLB 2030/4885PSMB1 1444/4885 |
| US-20170166572-A1 | NOVEL IMIDAZOTRIAZINONE OR IMIDAZOPYRAZINONE DERIVATIVES, AND USE THEREOF | TNKS1BP1, TPI1, TBKBP1 | KDM4E 1541/4885POLB 1996/4885PSMB1 1436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.